Asarfi Hospital Ltd provides primary health services & treatment and specialized super speciality health serviceBusiness Overview Asarfi Hospital Limited (AHL) operates three primary facilities:Pharmacy Contribution: The hospital’s pharmacy contributed 25% of the revenueAsarfi Cancer Institute (Ranguni, Dhanbad)Future Expansion: The facility is approved for construction of up to seven floors, enabling...
Asarfi Hospital's Q1 FY26 investor presentation reveals robust performance. Consolidated revenue surged 56% year-on-year to ₹35.68 Cr, with PAT more than doubling by 115% to ₹3.12 Cr. EBITDA margin stood strong at 20%. Patient volumes increased 40%, and occupancy rates improved across both super-specialty (64%) and cancer hospitals (42%). A...
Asarfi Hospital Limited has announced a virtual individual call between management and investors/analysts to discuss publicly available information. No unpublished price-sensitive information will be shared. This interaction helps maintain transparency and keeps shareholders informed about the company’s ongoing activities and outlook without disclosing sensitive details.
Asarfi Hospital Limited has announced a board meeting to appoint CS Sudipa Singh as the Compliance Officer and Company Secretary. Sudipa Singh, a qualified Company Secretary and law graduate, brings experience in secretarial, legal, and finance functions, including compliance, board processes, and acquisitions. She is not related to any company...
Asarfi Hospital Limited has announced a virtual one-on-one investor meet where the Managing Director, CFO, VP Finance, and Chief Manager Finance participated. The discussion was limited to publicly available information with no unpublished price-sensitive data shared. This engagement reflects the company’s commitment to transparent communication with institutional investors and analysts,...
Asarfi Hospital Limited has announced a board meeting to discuss the financial results for the quarter and half-year. The company has scheduled a conference call with analysts and investors to review the audited financial results for the quarter and year ended March 31, 2025. This session aims to provide clarity...
